Director Buys $500,000 Worth of Palvella Therapeutics Shares After Phase 3 Win

Jenkins acquired 4,000 shares in Palvella Therapeutics' underwritten public offering at $125.00 per share on Feb. 27, 2026, totaling roughly $500,000. This is a disclosed insider participation in the offering and is a routine financing-related purchase with limited market impact.

Analysis

Jenkins acquired 4,000 shares in Palvella Therapeutics' underwritten public offering at $125.00 per share on Feb. 27, 2026, totaling roughly $500,000. This is a disclosed insider participation in the offering and is a routine financing-related purchase with limited market impact.